Risk Factors Update Summary

• The ongoing conflict in Israel may disrupt operations and hinder capital raising efforts. This change could significantly impact business continuity and financial stability.
• The company entered into a convertible loan agreement for up to $5,000 with 8% interest. This could significantly impact liquidity and operational funding.
• Selling, general and administrative expenses surged to $35,134 in 2023 from $15,589 in 2022, representing a significant increase of 125%.
• The accumulated tax loss carryforward increased from approximately $22 million to $36 million as of December 31, 2023. This change might result in significant tax benefits for the company.
• The company reported a credit loss on convertible loan receivable of $2,688, compared to $0 in 2022. This indicates increased financial risk.
• The relevance of historical billing and collection data is now emphasized as critical for analysis. This change might result in improved forecasting accuracy.
• Ms. Caplan's reimbursement for expenses increased from $2,536 in 2022 to $2,627 in 2023. This change might result in increased scrutiny of executive compensation.
• A material weakness in internal controls over financial reporting was identified, potentially affecting timely and accurate financial reporting. This could lead to regulatory actions and investor confidence issues.
• New guidance on joint ventures aims to reduce accounting diversity, impacting investor tracking of contributions. This change might result in reduced basis differences for investors.
• The conversion price for outstanding loans was reduced from $7.00 to $2.50, potentially increasing share dilution.
• The company reported a net loss of $64,918 for the year ended December 31, 2023, compared to $12,169 in 2022. This significant increase raises concerns about financial stability.
• The company may face a liquidity crisis if it fails to comply with Nasdaq's minimum bid price requirement of $1.00 per share for 30 consecutive business days. This could result in delisting and reduced capital access.
• The FASB issued ASU 2023-07, enhancing segment disclosures, requiring significant segment expenses to be reported. This change may improve transparency for investors.
• The company reported stock-based compensation expenses to executive officers increased from $247 thousand to $690 thousand for the year ended December 31, 2023. This change indicates higher compensation costs.
• Impairment expenses for 2023 were $699, compared to $1,061 in 2022, reflecting ongoing challenges in asset valuation.
• The maturity date for several convertible loans was extended to January 31, 2026, affecting repayment timelines and financial planning.
• The Company contributed $79,728 to Swiss plans in 2023, down from $89,564 in 2022. This change might indicate a shift in employee benefits strategy.
• The total options granted under the Global Share Incentive Plan decreased from 3,023,518 to 1,415,008 as of December 31, 2023. This change may affect employee retention and motivation.
• The company faces delisting risk after receiving a notice from Nasdaq due to non-compliance with the minimum bid price requirement of $1.00 per share.
• The Company recorded a net loss of $5,343 due to deconsolidation of Octomera, affecting financial statements. This change highlights potential risks in investment valuations.
• The company awarded warrants to purchase 840,000 shares at $0.85 per share, which may influence investor sentiment and stock price.
• Ms. Assa Kunik's salary decreased from $162,316 in 2022 to $126,933 in 2023. This change might reflect cost-cutting measures within the organization.
• Impairment charges of $699 were recorded for investments during the year ended December 31, 2023, indicating potential risks in asset valuations.
• As of December 31, 2023, Koligo received $735 under the Koligo Convertible Loan Agreement, enhancing its financial position.
• The deconsolidation of Octomera at June 30, 2023, has materially impacted revenue recognition and financial stability.
• The company has incurred negative cash flows from operating activities of $14,837 in 2023, highlighting ongoing liquidity challenges.
• The total audit fees increased to $267,000 in 2023 from $295,110 in 2022. This change might suggest heightened regulatory compliance efforts.
• The Company’s equity investment in Octomera was valued at approximately $0 as of December 31, 2023, indicating significant financial implications for stakeholders.
• The company has an accumulated tax loss carryforward of approximately $10 million in its Israeli subsidiary as of December 31, 2023, down from $11 million. This change may impact future tax liabilities.
• The Company is evaluating new income tax disclosure guidance, which may enhance transparency regarding tax information for investors.
• The fair value of RSUs granted to employees increased to $50 thousand for the year ended December 31, 2023, indicating a shift in compensation strategy.
• The Company recognized total revenue of $530,000 for the year ended December 31, 2023. This change might indicate growth in service offerings.
• The company’s accumulated deficit increased to $176,622 as of December 31, 2023, raising concerns about long-term viability.